Bortezomib inhibits NF-κB, enhancing the susceptibility of MM plasma cells to therapeutics, while the induction of IL-6 by BMSCs mediated by NF-κB increases the secretion of VEGF from MM-PCs. The gene discussed is IL6; the disease is Miyoshi myopathy.